Opportunistic infections associated with TNF-α treatment

Future Rheumatology

Volumn 2, Issue 6, 2007, Pages 567-576

  Orenstein, Robert ^a   Matteson, Eric L ^a  

^a Mayo Clinic   (United States)

Author keywords

Adalimumab; Etanercept; Infliximab; Opportunistic infections; TNF inhibitors

Indexed keywords

ACICLOVIR; ADALIMUMAB; AMPHOTERICIN B LIPID COMPLEX; ANTIVIRUS AGENT; AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DIPHTHERIA PERTUSSIS TETANUS VACCINE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; FAMCICLOVIR; FLUCONAZOLE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HEPATITIS A VACCINE; HEPATITIS B VACCINE; INACTIVATED VACCINE; INFLIXIMAB; INFLUENZA VACCINE; ITRACONAZOLE; LIVE VACCINE; MERCAPTOPURINE; METHOTREXATE; PLACEBO; POLIOMYELITIS VACCINE; PREDNISONE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNINDEXED DRUG; VALACICLOVIR; VARICELLA ZOSTER VACCINE;

ASPERGILLOSIS; BACTERIAL INFECTION; BIBLIOGRAPHIC DATABASE; CANDIDIASIS; CELLULITIS; CLINICAL PRACTICE; CLINICAL TRIAL; COCCIDIOIDOMYCOSIS; CRYPTOCOCCOSIS; CYTOMEGALOVIRUS INFECTION; DIPHTHERIA; DRUG EFFICACY; EXTRAPULMONARY TUBERCULOSIS; HEPATITIS A; HEPATITIS B; HEPATITIS C; HERPES SIMPLEX; HERPES ZOSTER; HISTOPLASMOSIS; HOST PATHOGEN INTERACTION; HUMAN; IMMUNITY; INFECTION RISK; INFLUENZA; LEGIONNAIRE DISEASE; LEISHMANIASIS; LISTERIOSIS; LUNG INFECTION; MICROSPORIDIOSIS; MOLLUSCUM CONTAGIOSUM; MYCOBACTERIOSIS; MYCOSIS; NOCARDIOSIS; OPPORTUNISTIC INFECTION; PARASITOSIS; PERTUSSIS; PNEUMOCYSTIS PNEUMONIA; PNEUMONIA; POLIOMYELITIS; PRIORITY JOURNAL; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; RICKETTSIOSIS; RISK ASSESSMENT; RISK REDUCTION; SALMONELLOSIS; SKIN INFECTION; SOFT TISSUE INFECTION; TETANUS; TOXOPLASMOSIS; TUBERCULOSIS; VACCINATION; VIRUS INFECTION;

EID: 37749047206     PISSN: 17460816     EISSN: None     Source Type: Journal    
DOI: 10.2217/17460816.2.6.567     Document Type: Review

References (85)

1. Furst DE, Breedveld FC, Kalden JE et al.: Updated consensus statement on biological agents, specifically tumor necrosis factor α blocking agents and interleukin-1 receptor antagonist, for the treatment of rheumatic diseases, 2005. Ann. Rheum. Dis. 64(Suppl. IV), IV2-IV14 (2005).
2. Dinarello C: Anticytokine therapeutics and infections. Vaccine 21, S24-S34 (2003).
3. Gardam MA, Keystone EC, Menzies R et al.: Anti-tumour necrosis factor agents and tuberculosis risk: mechanism of action and clinical management. Lancet Infect. Dis. 3, 148-155 (2003).
4. Lin PL, Pawar S, Zinovik A et al.: TNF and chemokine expression in granulomas on non-human primates infected with M. tuberculosis. Presented at: Annual Meeting of the Infectious Diseases Society of America. Boston, MA, USA (Abstract) (2004).
5. Wallis RS, Ehlers S: Tumor necrosis factor and granuloma biology: explaining the differential infection risk if etanercept and infliximab. Semin. Arthritis Rheum. 34(Suppl. 1), 34-38 (2005).
6. Dinarello CA: Differences between antitumor necrosis factor a monoclonal antibodies and soluble TNF-receptor antagonists in host defense impairment. J. Rheum. Suppl. 74, 40-47 (2005).
7. Deepe GS, Gibbons RS: T cells require tumor necrosis Factor-α to provide protective immunity in mice infected with Histoplasma capsulatum. J. Infect. Dis. 193, 322-330 (2006).
8. Keane J: TNF-blocking agents and tuberculosis: new drugs illuminate an old topic. Rheumatology 44, 714-720 (2005).
9. Zganiacz A, Santosuosso M, Wang J et al.: TNF-α is a critical negative regulator of type 1 immune activation during intracellular bacterial infection. J. Clin. Invest. 113, 401-413 (2004).
10. Netea MG, Radstake T, Joosten LA et al.: Salmonella septicemia in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy. Association with decreased interferon γ production and Toll-like receptor 4 expression. Arthritis Rheum. 48, 1853-1857 (2003).
11. Alexopoulou L, Kranidioti K, Xantharea S et al.: Transmembrane bound TNF protects mutant mice against intracellular bacterial infection and autoimmune diseases. Eur. J. Immunol. 36, 2768-2780 (2007).
12. Zalevsky J, Secher J, Ezhevsky SA et al.: Dominant negative inhibitors of soluble TNF attenuate experimental arthritis without suppressing innate immunity to infection. J. Immunol. 179, 1872-1883, (2007).
13. Westhovens R, Yocum D, Han J et al.: The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities. A large randomized, placebo-controlled trial (The START trial). Arthritis Rheum. 54, 1075-1086 (2006).
14. Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE: Frequency of infection in patients with rheumatoid arthritis compared with controls. Arthritis Rheum. 46, 2287-2293 (2002).
15. Franklin J, Lunt M, Bunn D, Symmons D, Silman A: Risk and predictors of infection leading to hospitalization in a large primary-care-derived cohort of patients with inflammatory polyarthritis. Ann. Rheum. Dis. 66, 308-312 (2007).
16. Enbrel®, Package insert. Immunex Corporation, CA, USA.
17. Humira®, Package insert. Abbott Laboratories, II, USA.
18. Remicade®, Package insert. Centocor, Inc., PA, USA.
19. Sandborn WJ, Loftus EV: Balancing the risks and benefits of infliximab in the treatment of inflammatory bowel disease. Gut 53, 780-782 (2004).
20. Colombel JF, Loftus EV Jr, Tremaine WJ et al.: The safety profile of infliximab in patients with Crohn's disease: the Mayo Clinic experience in 500 patients. Gastroenterology 126, 19-31 (2004).
21. Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M et al., the TEMPO study investigators: Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double blind randomized controlled trial. Lancet 363, 675-681 (2004).
22. Salliot C, Gossec L, Ruyssen-Witrand A et al.: Infections during minor necrosis factor α blocker therapy for rheumatic diseases in daily practice: a systematic retrospective study of 709 patients. Rheumatology 46, 227-234 (2007).
23. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V: Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies. Systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295, 2275-2285 (2006).
24. Wallis RS, Broder M, Wong J, Beenhower D: Granulomatous infections due to tumor necrosis factor blockade: correction. Clin. Infect. Dis. 39, 1254-1255 (2004).
25. Wallis RS, Broder M, Wong J, Beenhower D: Granulomatous infections associated with tumor necrosis factor antagonists. Clin. Infeet. Dis. 38, 1261-1265 (2004).
26. Carmona L, Gomez-Reino JJ, Rodriguez-Valverde, BIOBADASER Group: Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor a antagonists. Arthritis Rheum. 52, 1766-1772 (2005).
27. Dixon WG, Hyrich KL, Watson K, Symmons DPM, Saman AJ and the BSR Biologics Register: Serious infection rates in patients receiving biologic therapy in the United Kingdom: results from the BSR Biologics Register. Presented at: EULAR. Vienna, Austria, June 8-11 (Abstract OP0094) (2005).
28. Tubach F, Salmon-Ceron D, Ravaud P, Mariette X, RATIO study group: The RATIO observatory: French registry of opportunistic infections, severe bacterial infections, and lymphomas complicating anti-TNF α therapy. Joint Bone Spine 72, 456-460 (2005).
29. Listing J, Stranfeld A. Kary S et al.: Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum. 52, 3403-3412 (2005).
30. Dixon WG, Watson K, Lunt M et al.: Rates of serious infection, including site-specific and bacterial intracellular infection in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy. Arthritis Rheum. 54, 2368-2376 (2006).
31. Dixon WG, Symmons DPM, Lunt KD et al.: Serious infection following and-tumor necrosis factor a therapy in patients with rheumatoid arthritis. Arthritis Rheum. 56, 2896-2904 (2007).
32. Curtis JR, Patkar N, Xie A et al.: Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor α antagonists. Arthritis Rheum. 56, 1125-1133 (2007).
33. Gluck T, Linde HJ, Scholmerich J, Muller-Ladner U, Fiehn C, Bohland P: Anti-tumor necrosis factor therapy and Listeria monocytogenes infection: report of two cases. Arthritis Rheum. 46, 2255-2257 (2002).
34. Slifman NR, Gershon SL, Lee KH, Edwards ET, Braun MM: Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor α neutralizing agents. Arthritis Rheum. 48, 319-324 (2003).
35. Ellerin T, Rubin RH, Weinblatt ME: Infections and anti-tumor necrosis factor α therapy. Arthritis Rheum. 11, 3013-3022 (2003).
36. Cornillie F, Shealy D, D'Haens G et al.: Infliximab induces potent anti-inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn's disease. Aliment. Pharmacol. Ther. 15, 463-473 (2001).
37. Fu A, Bertouch JV, McNeil HP: Disseminated Salmonella typhimurium infection secondary to infliximab treatment. Arthritis Rheum. 50, 3049 (2004).
38. Claudepierre P, Deprez X, Goupille P et al., Club Rheumatismes et Inflammation, French Society of Rheumatology: Anti-TNF a therapy and safety monitoring: clinical tool guide. Joint Bone Spine 72(Suppl. 1), S1-S58 (2005).
39. Fleischman R, Yocum D: Does safety make a difference in selecting the right TNF antagonist? Arthritis Res Ther. 6(Suppl. 2), S12-S18 (2004).
40. Winthrop KL, Siegel JN, Jereb J, Taylor Z, Iademarco MF: Tuberculosis associated with therapy against tumor necrosis factor α. Arthritis Rheum. 52, 2968-2974 (2005).
41. Wolfe F, Michaud K Anderson J, Urbansky K: Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthritis Rheum. 50, 372-379 (2004).
42. Centers for Disease Control and Prevention: Tuberculosis associated with blocking agents against minor necrosis factor-α - California, 2002-2003. MMWR 53, 683-686 (2004).
43. Ormerod LP, British Thoracic Society Standards of Care Committee: BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start and-TNF-α treatment. Thorax 60, 800-805 (2005).
44. Gomez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD: Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum. 48, 2122-2127 (2003).
45. Perez JL, Kupper H, Spencer-Green GT: Impact of screening for latent TB prior to initiating anti-TNF therapy in North America and Europe. Presented at: The Annual Congress of the European League Against Rheumatism. Vienna, Austria, 8-11 June 8-11 (Abstract OP0093) (2005).
46. Hernandez-Cruz B, Ponce-de-leon-Rosales S, Sifuentes-Osornio J, Ponce-de-leon- Garduno A, Diaz-Jouanen E: Tuberculous prophylaxis in patients with steroid treatment and systemic rheumatic disease. A case control study. Clin. Exp. Rheumatol. 17, 81-87 (1999).
47. Lalvani A, Richeldi L, Kunst H: Interferon γ assays for tuberculosis. Lancet Infect. Dis. 5, 322-323 (2005).
48. American Thoracic Society, Centers for Diseases Control, Infectious Diseases Society of America: Treatment of tuberculosis. Am. J. Respir. Crit. Care Med. 167, 603-662 (2003).
49. Vidal CG, Fernandez SR, Lacasa JM et al.: Paradoxical response to antituberculous therapy in infliximab treated patients with disseminated tuberculosis. Clin. Infect. Dis. 40, 756-759 (2005).
50. Narita M, Ashkin D, Hollender E, Pitchenik A: Paradoxical worsening of tuberculosis following antiretroviral therapy in patients with AIDS. Am. J. Respir. Crit. Care Med. 158, 157-161 (1999).
51. Wood KL, Hage CA, Knox KS et al.: Histoplasmosis after treatment with anti- TNF therapy. Am. J. Crit. Care Med. 167, 1279-1283 (2003).
52. Hage CA, Wheat LJ, Twigg HL, Knox KS: Infliximab does not affect dendritic cells' mediated lymphoproliferative response to Histoplasma capsulatum. Clin. Infect. Dis. 41, 1685-1687 (2006).
53. Smith JG, Williams DM, Graybill JR: Tumor necrosis factor-α plays a role in host defense against Histoplasma capsulatum. J. Infect. Dis. 162, 1349-1353 (1990).
54. Lee JH, Slifman NR, Gershon SK et al.: Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor α antagonist's infliximab and etanercept. Arthritis Rheum. 46, 2565-2570 (2002).
55. Nakelchik M, Mangino JE: Reactivation of histoplasmosis after treatment with infliximab. Am. J. Med. 112, 78-79 (2002).
56. Wheat JL, Freifeld AG, Kleiman MB et al.: Clinical practice guidelines for the management of patients with histoplasmosis. 2007 update from the Infections Diseases Society of America. Clin. Infect. Dis. 45, 807-825 (2007).
57. Vail GM, Young RS, Wheat LJ, Filo RS, Cornetta K, Goldman M: Incidence of histoplasmosis following allogeneic bone marrow transplant or solid organ transplant in a hyperendemic area. Transpl. Infect. Dis. 4, 148-151 (2002).
58. McKinsey DS, Wheat LJ, Cloud GA et al.: Itraconazole prophylaxis for fungal infections in patients with advanced human immunodeficiency virus infection: randomized, placebo-controlled double blind study. Clin. Infect. Dis. 28, 1049-1056 (1999).
59. Bergstrom L, Yocum DE, Ampel NM et al.: Increased risk of coccidioidomycosis in patients treated with tumor necrosis factor α antagonists. Arthritis Rheum. 50, 1959-1966 (2004).
60. Blair JE, Douglas DD, Mulligan DC: Early results of targeted prophylaxis for coccidioidomycosis in patients undergoing orthotopic Ever transplantation within an endemic area. Transpl. Infect. Dis. 5, 3-8 (2003).
61. Dewsnup DH, Galgiani JN, Graybill JR et al.: Is it ever safe to stop azole therapy for Coccidioides immitis meningitis? Ann. Intern. Med. 124, 305-310 (1996).
62. Thomas CF, Eimper AH: Pneumocystis pneumonia. N. Engl. J. Med. 350, 2487-9248 (2004).
63. Ding K, Shibui A, Yang Y, Takamoto M, Matsuguchi T, Sugame K: Impaired recognition by Toll-like receptor 4 is responsible for exacerbated murine Pneumocystis pneumonia. Microbes Infect. 7, 195-203 (2005).
64. Tai TL, O'Rourke KP, McWeeney M, Burke CM, Sheehan K, Barry M: Pneumocystis carinii pneumonia following a second infusion of infliximab. Rheumatology 41, 951-952 (2002).
65. Velayos FS, Sandbom WJ: Neumocystis carinii pneumonia during maintenance anti-tumor necrosis factor α therapy with infliximab for Crohn's disease. Inflamm. Bowel Dis. 10, 657-660 (2004).
66. Kaur N, Mahl TC: Neumocystis jiroveci (carinii) pneumonia after infliximab therapy: a review of 84 cases. Dig. Dis. Sci. 52, 1481-1484 (2007).
67. Crum NF, Lederman ER, Wallace MR: Infections associated with tumor necrosis factor α antagonists. Medicine 84, 291-302 (2005).
68. Warris A, Bjorneklett, Gaustad P: Invasive aspergillosis associated with infliximab therapy. N. Engl. J. Med. 14, 1099 (2001).
69. DeRosa FG, Shaz D, Campagna AC, Dellaripa PF, Khettry U, Craven DE: Invasive pulmonary aspergillosis soon after therapy with infliximab, a tumor necrosis factor α neutralizing anribody: a possible healthcare associated case? Infect. Control Hosp. Epidemiol. 24, 7 (2003).
70. Coyle CM, Weis LM, Rhodes LV et al.: Fatal myositis due to the microsporidian Brachiola algerae, a mosquito pathogen. N. Engl. J. Med. 351, 42-47 (2004).
71. Gottlieb GS, Lesser CF, Holmes KK, Wald A: Disseminated sporotrichosis associated with treatment with immunosuppressants and tumor necrosis factor α antagonists. Clin. Infect. Dis. 37, 838-840 (2003).
72. Haerter G, Manfras BJ, de Jong-Hesse et al.: Cytomegalovirus retinitis in a patient treated with anti-tumor necrosis factor α antibody therapy rheumatoid arthritis Clin. Infect. Dis. 39, E88-E94 (2004).
73. Esteve M, Saro C, Gonzales-Huix F, Forne M, Viver JM: Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis. Gut 1363-1365 (2004).
74. Ostuni P, Botsios C, Punzi L et al.: Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid arthritis treated with infliximab and low dose methorrexate. Ann. Rheum. Dis. 62, 686-687 (2003).
75. Calabrese LH, Zein N, Vassilopoulos D: Safety of antitumor necrosis factor therapy in patients with chronic viral infections: hepatitis C, hepatitis B, and HIV infection. Ann. Rheum. Dis. 63(Suppl. II), 1118-1124 (2004).
76. Balandraud N, Roudier J, Roudier C: What are the links between Epstein-Barr virus, lymphoma, and tumor necrosis antagonism in rheumatoid arthritis? Semin. Arthritis Rheum. 34(Suppl. 1), 31-33 (2005).
77. Swindell K, Goldfarb J, Danziger-Isakov L, Sabella C: Herpes zoster after infliximab for Crohn's disease in adolescent patients. Presented at: 42nd Annual Meeting of the Infectious Diseases Society of America. Boston, MA, USA, September 30 - October 3 (Abstract 999) (2004).
78. Wolfe F, Michaud K: Rates and risk factors for herpes zoster in patients with rheumatoid arthritis. Presented at: EULAR. Vienna, Austria, June 8-11 (Abstract OP0149) (2004).
79. Cursiefen C, Grunke M, Dechant C, Antoni C, Junemann A, Holbach LM: Multiple bilateral eyelid molluscum contagiosum lesions associated with TNF α-antibody and methotrexate therapy. Am. J. Ophthalmol. 134, 270-271 (2002).
80. Wallis RS, Kyambadde P, Johnson JL et al.: A study of the safety, immunology, virology and microbiology of adjunctive etanercept in HIV-1 associated tuberculosis. AIDS 18, 257-264 (2004).
81. Mariette X, Salmon D: French guidelines for diagnosis and treating latent and active tuberculosis in patients with RA treated with TNF blockers. Ann. Rheum. Dis. 62, 791 (2003).
82. Ledingham. J, Wilkinson C, Deighton C: British Thoracic Society recommendations for assessing risk and managing tuberculosis in patients due to start and-TNF-α treatments. Rheumatology 44, 1205-1206 (2005).
83. Orenstein R: Travel in patients receiving TNF-α inhibitors. Travel Med. Infect. Dis. 3, 105-109 (2005).
84. Elkyam O, Caspi D, Reitblatt T, Charboneau D, Rubins JB: The effect of tumor necrosis factor blockade on the response to pneumococcal vaccination in patients with rheumatoid arthritis and ankylosing spondylitis. Siminars Arthritis Rheum. 33, 283-288 (2004).
85. Fomin I, Caspi D, Levy V, et al.: Vaccination against influenza in rheumatoid arthritis patients: the effect of disease modifying drugs, including TNF α blockers. Arthritis Rheum. 65, 191-194 (2006).